Latest News for KYKOF
Kyowa Kirin on Tuesday said it is discontinuing all ongoing trials of its experimental drug to treat skin conditions.
Kyowa Kirin Co., Ltd. and Amgen Inc. (NASDAQ: AMGN) terminated on Friday the current rocatinlimab development and commercialization collaboration.
Kyowa Kirin Co., Ltd. (OTCMKTS:KYKOF - Get Free Report) shares were down 4.5% during mid-day trading on Tuesday. The stock traded as low as $15.8450 and last traded at $15.8450. Approximately 1,957 shares changed hands during trading, an increase of 174% from the average daily volume of 714 shares. The stock had previously closed
TOKYO--(BUSINESS WIRE)--Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the Board of Directors' decision to appoint Abdul Mullick, Ph.D., currently President and Chief Operating Officer (COO), to the role of President and Chief Executive Officer (CEO). The appointment will become effective March 2026 following the conclusion of the Ordinary…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for KYKOF.
Senate Trading
No Senate trades found for KYKOF.
U.S. House Trading
No House trades found for KYKOF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.